Stocks · News reference
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Arcutis Biotherapeutics reported strong third-quarter 2026 financial results, highlighted by $143.9 million in ZORYVE net product revenue and an upward revision to its full-year 2026 sales guidance.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Arcutis Biotherapeutics Insider Executes Share Sale
An insider at Arcutis Biotherapeutics sold shares valued at approximately $1.4 million, as disclosed in a recent SEC filing.
Arcutis Biotherapeutics Initiates Phase 3 Study for ZORYVE Cream 0.3%
Arcutis Biotherapeutics has enrolled the first participant in its Phase 3 INTEGUMENT-3 clinical trial, evaluating the efficacy and safety of ZORYVE (roflumilast) cream 0.3% for moderate to severe atopic dermatitis.
Arcutis Biotherapeutics Q3 EPS $0.06 Misses $0.12 Estimate, Sales $143.919M Beat $142.592M Estimate
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings
Arcutis Biotherapeutics Appoints Rob Scott, MD to Board of Directors
Arcutis Biotherapeutics, Inc. has appointed pharmaceutical industry veteran Rob Scott, MD, to its Board of Directors, effective October 23, 2026.